Video Experimental Relacionado
Updated: Aug 4, 2026
12:30
A Comprehensive Protocol for Manual Segmentation of the Medial Temporal Lobe Structures
Published on: July 2, 2014
Atrofia de rápido progreso del lóbulo temporal medial en la enfermedad de Alzheimer
K A Jobst1, A D Smith, M Szatmari
1University Department of Pharmacology, Radcliffe Infirmary, Oxford, UK.
Lancet (London, England)
|April 2, 1994
Resumen
La enfermedad de Alzheimer causa una rápida atrofia del lóbulo temporal medial al 15.1% anual, lo que excede significativamente las tasas normales de envejecimiento (1.5%). Esto sugiere que el Alzheimer es un proceso de enfermedad distinto, no un envejecimiento acelerado.
Área de la Ciencia:
- Neurología Neurología.
- La neurociencia es la neurociencia.
- Gerontología Gerontología.
Sus antecedentes:
- La enfermedad de Alzheimer (EA) se caracteriza por la pérdida de neuronas y cambios patológicos en el lóbulo temporal medial.
- Comprender la tasa de atrofia cerebral en la enfermedad de Alzheimer es crucial para diferenciarla del envejecimiento normal.
Objetivo del estudio:
- Para cuantificar la tasa de atrofia del lóbulo temporal medial en pacientes con enfermedad de Alzheimer confirmada.
- Para comparar la tasa de atrofia en los pacientes con enfermedad de Alzheimer con la de los individuos de envejecimiento sanos.
Principales métodos:
- Se utilizaron tomografías computarizadas orientadas al lóbulo temporal (TC) anuales para medir la atrofia.
- El estudio incluyó a 20 pacientes con enfermedad de Alzheimer confirmada histopatológicamente y 47 controles sanos.
Principales resultados:
- Los pacientes con enfermedad de Alzheimer presentaron una tasa promedio de atrofia del lóbulo temporal medial del 15,1% por año.
- Los controles de envejecimiento saludable mostraron una tasa de atrofia significativamente menor del 1,5% por año.
Conclusiones:
- La atrofia excesiva del lóbulo temporal medial en la enfermedad de Alzheimer sugiere un proceso patológico único.
- Es probable que la enfermedad de Alzheimer sea un proceso de enfermedad distinto en lugar de una aceleración del envejecimiento normal.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...